Microcystic mesothelioma is classified as a rare subtype of mesothelioma, distinguished by the numerous small cystic cavities observed within the tumor. Protheragen has wide-ranging services focused on developing diagnostics and therapeutics specific to microcystic mesothelioma. We offer complete, integrated services to support the entire drug development process, from initial drug identification through to preclinical testing.
Overview of Microcystic Mesothelioma
Microcystic mesothelioma is a particularly uncommon and deadly subtype of malignant mesothelioma that mostly manifests in the pleura and peritoneum. Its distinctive growth pattern includes mesothelial cells forming microcystic structures. Unlike the rest of the mesotheliomas, microcystic mesothelioma has a peculiar histopathological pattern, which complicates diagnosis and therapy. It is most often associated with chronic exposure to asbestos fibers, although some studies suggest other alternatives, like erionite exposure. The focus of our attention is the microcystic mesothelioma of the pleura, which is still a significant problem in the field of oncology, and this is because of the silent, progressive nature of the illness, coupled with aggressive characteristics and generalized resistance to therapy.
Fig.1 Embryology of the mesothelium. (Bonde A.,
et al., 2023)
Pathogenesis of Microcystic Mesothelioma
Microcystic mesothelioma has several causes, with exposure to asbestos being the main one. The inhalation of asbestos fibers can become embedded in the pleural space, which incites a prolonged inflammatory response. Inflammation of this nature causes macrophages to release reactive oxygen species (ROS) and reactive nitrogen species (RNS), which lead to inflammation, DNA damage, and mutations in mesothelial cells. Some genetic factors, such as mutations in the BAP1 gene, which is associated with DNA repair, increase a person’s risk of developing mesothelioma. In addition to this, the pathogenesis of mesothelioma is believed to be linked to certain viruses, such as SV40, but their exact role is still being studied.
Diagnostics Development for Microcystic Mesothelioma
- Next-Generation Sequencing (NGS)
NGS technologies allow for comprehensive genetic profiling of tumor samples. NGS enables the identification of somatic mutations, copy number alterations, and gene expression signatures that are unique to microcystic mesothelioma. This molecular information not only aids in diagnosis but also provides prognostic information, helping clinicians to predict disease outcomes and tailor therapeutic strategies.
- Immunohistochemistry (IHC)
Immunohistochemistry remains one of the cornerstone methods for diagnosing microcystic mesothelioma. A panel of IHC markers, such as Calretinin, EMA (epithelial membrane antigen), and WT1 (Wilms tumor 1), is used to distinguish mesothelioma from other malignancies. However, due to the overlapping expression of these markers with other cancers, a comprehensive panel approach is essential for accurate diagnosis.
- Biomarker Discovery
Serum biomarkers, such as soluble mesothelin-related peptides (SMRP), are being investigated as non-invasive diagnostic tools for microcystic mesothelioma. These biomarkers are released into the bloodstream by tumor cells and can potentially be used to detect the disease at an early stage. Ongoing research is focused on identifying new biomarkers that could provide more sensitive and specific diagnostic capabilities.
Therapeutics of Microcystic Mesothelioma
| Therapeutics |
Drug Name |
Mechanism |
Description |
Stage |
| Chemotherapy |
Pemetrexed (Alimta) |
Folate analog that inhibits enzymes involved in DNA synthesis |
Standard first-line therapy in combination with cisplatin for unresectable pleural mesothelioma |
Approved |
| Cisplatin |
Platinum-based alkylating agent that cross-links DNA strands |
Often combined with pemetrexed, the cornerstone of mesothelioma chemotherapy regimens |
Approved |
| Immunotherapy |
Nivolumab (Opdivo) |
PD-1 inhibitor that enhances T-cell-mediated immune response |
Approved in combination with ipilimumab for first-line therapy of unresectable mesothelioma |
Approved |
| Ipilimumab (Yervoy) |
A CTLA-4 inhibitor that stimulates T-cell activity |
Used in combination with nivolumab to improve survival in mesothelioma patients |
Approved |
| Pembrolizumab (Keytruda) |
PD-1 inhibitor that blocks the immune checkpoint to activate T-cells |
Recently approved for mesothelioma in combination with chemotherapy, showing improved survival rates |
Approved |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Protheragen understands that each project is unique, and we offer customized services to meet the specific requirements of our clients. Our team works closely with clients to design and implement tailored research strategies, ensuring that each project is optimized for success. Whether it is developing a novel diagnostic assay or evaluating a new therapeutic agent, our customized services provide the flexibility and expertise needed to drive innovation in microcystic mesothelioma research.
Disease Models
- Primary Cell Cultures
- Organoid Models
- BAP1 Mutant Mouse Models
- Subcutaneous Xenograft Models
- Orthotopic Xenograft Models
Protheragen's diagnostics and therapeutics development services are characterized by our commitment to scientific excellence and innovation. Our state-of-the-art facilities are equipped with the latest technologies, enabling us to provide accurate and reliable diagnostic assays and robust preclinical research. If you are interested in our services, please feel free to contact us.
Reference
- Bonde, Apurva, et al. "Mesotheliomas and benign mesothelial tumors: update on pathologic and imaging findings." Radiographics 43.3 (2023): e220128.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
